Should I buy or sell Procaps Group stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Procaps Group in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PROC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROC, but not buy additional shares or sell existing shares. View PROC analyst ratings or view top-rated stocks .

What is Procaps Group's stock price target for 2024?

1 Wall Street analysts have issued twelve-month target prices for Procaps Group's shares. Their PROC share price targets range from $4.50 to $4.50. On average, they anticipate the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price. View analysts price targets for PROC or view top-rated stocks among Wall Street analysts .

How have PROC shares performed in 2024?

Procaps Group's stock was trading at $4.07 at the beginning of the year. Since then, PROC stock has decreased by 36.1% and is now trading at $2.60. View the best growth stocks for 2024 here .

When is Procaps Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024. View our PROC earnings forecast .

How were Procaps Group's earnings last quarter?

Procaps Group S.A. (NASDAQ:PROC) announced its quarterly earnings results on Tuesday, December, 26th. The company reported $0.05 EPS for the quarter, meeting analysts' consensus estimates of $0.05. The business had revenue of $118.41 million for the quarter, compared to analysts' expectations of $110.40 million. Procaps Group had a trailing twelve-month return on equity of 283.06% and a net margin of 12.61%.

How do I buy shares of Procaps Group?

Shares of PROC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PROC

Procaps Group (PROC) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free PROC Stock Alerts

$2.60

-0.09 (-3.35%)

(As of 04/15/2024 ET)

Compare

Today's Range: $2.55
▼
$2.60
50-Day Range: $2.60
▼
$3.70
52-Week Range: $1.95
▼
$5.38

Volume: 8,388 shs
Average Volume: 2,585 shs
Market Capitalization: N/A

P/E Ratio: 5.00
Dividend Yield: N/A
Price Target: $4.50

Get Procaps Group alerts:

Procaps Group MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 73.1% Upside
$4.50 Price Target
Short Interest: Healthy
0.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 13.33%
From $0.15 to $0.17 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.02 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Procaps Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Procaps Group has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.03% of the float of Procaps Group has been sold short.
Short Interest Ratio / Days to Cover
Procaps Group has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Procaps Group has recently increased by 12.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Procaps Group does not currently pay a dividend.
Dividend Growth
Procaps Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PROC.

3.3

News and Social Media Coverage

News Sentiment
Procaps Group has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Procaps Group this week, compared to 0 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Procaps Group insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.90% of the stock of Procaps Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Procaps Group are expected to grow by 13.33% in the coming year, from $0.15 to $0.17 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Procaps Group is 5.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Procaps Group is 5.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 166.67.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Procaps Group Stock (NASDAQ:PROC)

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

PROC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PROC Stock News Headlines

March 29, 2024 | finance.yahoo.com

Global Gummy Market Size To Worth USD 66.56 Billion By 2033 | CAGR of 11.32%

March 6, 2024 | investing.com

Procaps explores strategic alternatives to boost shareholder value

April 16, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

March 4, 2024 | finance.yahoo.com

Procaps Announces Formation of Strategic Committee to Explore Value Creation Alternatives

February 5, 2024 | finance.yahoo.com

Procaps Issues Shareholder Letter from New CEO

February 1, 2024 | finance.yahoo.com

Does This Valuation Of Procaps Group S.A. (NASDAQ:PROC) Imply Investors Are Overpaying?

January 21, 2024 | ca.finance.yahoo.com

Procaps Group S.A. (PROCW)

January 21, 2024 | seekingalpha.com

PROC Procaps Group S.A.

April 16, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

January 16, 2024 | finance.yahoo.com

Procaps Group – Notice to Shareholders

December 27, 2023 | msn.com

Pharma Company Procaps Beats On Q3 But Lowers FY23 Guidance: Here's Why

December 27, 2023 | msn.com

Procaps Group reports Q3 results; updates FY23 outlook

December 26, 2023 | msn.com

Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates

December 26, 2023 | finance.yahoo.com

Procaps Group Reports Third Quarter 2023 Results

November 29, 2023 | finance.yahoo.com

Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America

November 22, 2023 | marketwatch.com

Procaps Group Names Vieira to Succeed Minski as CEO

November 22, 2023 | markets.businessinsider.com

Procaps Group Appoints Jose Antonio Vieira To Succeed Ruben Minski As CEO

November 22, 2023 | msn.com

Procaps Group says CEO Minski to step down from the role

November 22, 2023 | finance.yahoo.com

Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

November 14, 2023 | finance.yahoo.com

Procaps Group Update on Third Quarter Results

November 10, 2023 | finance.yahoo.com

Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

November 5, 2023 | finance.yahoo.com

Procaps Group S.A. (NASDAQ:PROC) insiders have significant skin in the game with 60% ownership

October 29, 2023 | barrons.com

Procaps Group S.A. Wt

October 23, 2023 | finance.yahoo.com

Procaps Appoints Sandra Sánchez y Oldenhage to Board of Directors

October 16, 2023 | finance.yahoo.com

Procaps Group to Participate at CPHI Barcelona 2023

October 2, 2023 | finance.yahoo.com

Procaps Group to Host Webinar on Colombian Pharma Market

September 6, 2023 | finance.yahoo.com

Procaps Group S.A. (NASDAQ:PROC) Q2 2023 Earnings Call Transcript

See More Headlines

Receive PROC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Procaps Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/26/2023
Today: 4/15/2024
Next Earnings (Estimated): 6/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PROC
CUSIP: N/A
CIK: 1863362
Web: unionacquisitiongroup.com
Phone: 356 7995-6138
Fax: N/A
Employees: 5,500
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.50
High Stock Price Target: $4.50
Low Stock Price Target: $4.50
Potential Upside/Downside: +73.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.52
Trailing P/E Ratio: 5.00
Forward P/E Ratio: 17.33
P/E Growth: N/A
Net Income: $42.54 million
Net Margins: 12.61%
Pretax Margin: 16.36%
Return on Equity: 283.06%
Return on Assets: 11.04%

Debt

Debt-to-Equity Ratio: 5.74
Current Ratio: 1.47
Quick Ratio: 0.99

Sales & Book Value

Annual Sales: $409.92 million
Price / Sales: N/A
Cash Flow: $0.51 per share
Price / Cash Flow: 5.11
Book Value: ($0.02) per share
Price / Book: -130.00

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.13

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Ruben Minski (Age 71)
Founder & Executive Chairman
Mr. Jose Antonio Toledo Vieira (Age 57)
Chief Executive Officer
Mr. Patricio Vargas Munoz (Age 51)
Global Chief Financial Officer
Dr. Camilo Camacho (Age 50)
Chief Operations Officer
Ms. Melissa Angelini
Investor Relations Director
Ms. Marcela Carvajalino Pagano (Age 57)
Vice-President of Corporate & Legal Affairs
Mr. Luis Alberto Palacios Aragon (Age 60)
Vice-President of International Marketing and R&D
Mr. Mauricio Castaneda Caballero (Age 47)
Vice-President of Human Resources
Mr. Carlos Piocuda Russo (Age 39)
Head of Optimization of Corporate Value & Corporate VP of Finance

Key Competitors

View All Competitors

Institutional Ownership

Exome Asset Management LLC
Bought 126,901 shares on 2/15/2024
Ownership: 0.112%

View All Institutional Transactions

PROC Stock Analysis - Frequently Asked Questions

Should I buy or sell Procaps Group stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Procaps Group in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PROC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROC, but not buy additional shares or sell existing shares.
View PROC analyst ratings or view top-rated stocks.
What is Procaps Group's stock price target for 2024?: 1 Wall Street analysts have issued twelve-month target prices for Procaps Group's shares. Their PROC share price targets range from $4.50 to $4.50. On average, they anticipate the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for PROC or view top-rated stocks among Wall Street analysts.
How have PROC shares performed in 2024?: Procaps Group's stock was trading at $4.07 at the beginning of the year. Since then, PROC stock has decreased by 36.1% and is now trading at $2.60.
View the best growth stocks for 2024 here.
When is Procaps Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024.
View our PROC earnings forecast.

How were Procaps Group's earnings last quarter?: Procaps Group S.A. (NASDAQ:PROC) announced its quarterly earnings results on Tuesday, December, 26th. The company reported $0.05 EPS for the quarter, meeting analysts' consensus estimates of $0.05. The business had revenue of $118.41 million for the quarter, compared to analysts' expectations of $110.40 million. Procaps Group had a trailing twelve-month return on equity of 283.06% and a net margin of 12.61%.
How do I buy shares of Procaps Group?: Shares of PROC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial